aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
OrbiMed Advisors is a prominent investment firm based in New York City, specializing in the healthcare and biotechnology sectors. The firm invests globally across various stages, including Series A, B, C, and beyond, as well as in private equity and venture capital. OrbiMed's investments typically range from early-stage ventures to late-stage companies, focusing on biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Notable portfolio companies include AbCellera Biologics, Adaptive Biotechnologies, and Caris Life Sciences. Key partners include Samuel Isaly, Michael Sheffery, and Arvind Desai. OrbiMed's investment philosophy centers on driving innovation and improving patient outcomes. The firm offers tailored financing solutions and leverages a global team to support portfolio companies. Unique value-add services include strategic guidance and access to a vast network of industry experts.
Also Known As
Orbimed Advisors Llc.
Operating Status
Active
OrbiMed Advisors Address
San Francisco,
California
94158
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts